Regulation of MT1-MMP/MMP-2/TIMP-2 axis in human placenta

Journal of Inflammation Research

Volumn 8, Issue , 2015, Pages 193-200

  Vincent, Zoë L ^a,b   Mitchell, Murray D ^c   Ponnampalam, Anna P ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

DNA methylation; Epigenetic regulation; Labor; MMPs; Placenta

Indexed keywords

DECITABINE; DNA; GELATINASE A; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DEGRADATION; DNA EXTRACTION; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GESTATION PERIOD; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PLACENTA; PROMOTER REGION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA EXTRACTION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84943515951     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S88039     Document Type: Article

References (40)

1. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 1988; 48(12):3307–3312.
2. Weiss A, Goldman S, Shalev E. The matrix metalloproteinases (MMPS) in the decidua and fetal membranes. Front Biosci. 2007;12:649–659.
3. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491–21494.
4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839.
5. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–573.
6. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5(8):2145–2154.
7. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991;277(Pt 1):277–279.
8. Murphy G, Ward R, Hembry RM, Reynolds JJ, Kuhn K, Tryggvason K. Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J. 1989;258(2):463–472.
9. Hipps DS, Hembry RM, Docherty AJ, Reynolds JJ, Murphy G. Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler. 1991;372(4):287–296.
10. Woessner JF Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11–21.
11. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135–1149.
12. Fortunato SJ, Menon R, Lombardi SJ. Expression of a progelatinase activator (MT1-MMP) in human fetal membranes. Am J Reprod Immunol. 1998;39(5):316–322.
13. Athayde N, Romero R, Gomez R, et al. Matrix metalloproteinases-9 in preterm and term human parturition. J Matern Fetal Med. 1999;8(5): 213–219.
14. Xu P, Alfaidy N, Challis JR. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human placenta and fetal membranes in relation to preterm and term labor. J Clin Endocrinol Metab. 2002;87(3): 1353–1361.
15. Ota A, Yonemoto H, Someya A, Itoh S, Kinoshita K, Nagaoka I. Changes in matrix metalloproteinase 2 activities in amniochorions during premature rupture of membranes. J Soc Gynecol Investig. 2006;13(8):592–597.
16. Chelbi ST, Mondon F, Jammes H, et al. Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension. 2007;49(1):76–83.
17. Fortunato SJ, Menon R, Lombardi SJ. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture. J Perinat Med. 1999;27(5):362–368.
18. Maymon E, Romero R, Pacora P, et al. A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. J Perinat Med. 2001; 29(4):308–316.
19. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10(3):192–206.
20. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem. 2009;284(19):12727–12734.
21. Mitchell MD. Unique suppression of prostaglandin H synthase-2 expression by inhibition of histone deacetylation, specifically in human amnion but not adjacent choriodecidua. Mol Biol Cell. 2006;17(1):549–553.
22. Sato TA, Mitchell MD. Molecular inhibition of histone deacetylation results in major enhancement of the production of IL-1beta in response to LPS. Am J Physiol Endocrinol Metab. 2006;290(3):E490–E493.
23. Simpson KL, Keelan JA, Mitchell MD. Labor-associated changes in interleukin-10 production and its regulation by immunomodulators in human choriodecidua. J Clin Endocrinol Metab. 1998;83(12):4332–4337.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
25. Fortunato SJ, Menon R, Lombardi SJ. Amniochorion gelatinase-gelatinase inhibitor imbalance in vitro: a possible infectious pathway to rupture. Obstet Gynecol. 2000;95(2):240–244.
26. Skinner SJ, Campos GA, Liggins GC. Collagen content of human amniotic membranes: effect of gestation length and premature rupture. Obstet Gynecol. 1981;57(4):487–489.
27. Pulukuri SM, Patibandla S, Patel J, Estes N, Rao JS. Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene. 2007;26(36):5229–5237.
28. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457–463.
29. Terry SY, Vallis KA. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(4):1298–1305.
30. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 2002; 62(22):6456–6461.
31. Zheng Z, Li L, Liu X, et al. 5-Aza-2′-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J. 2012;26(1):449–459.
32. Schmelz K, Sattler N, Wagner M, Lübbert M, Dörken B, Tamm I. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005;19(1):103–111.
33. Zhu WG, Dai Z, Ding H, et al. Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene. 2001;20(53):7787–7796.
34. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem. 2009;284(19):12727–12734.
35. Couillard J, Estève PO, Pradhan S, St-Pierre Y. 5-Aza-2′-deoxycytidine and interleukin-1 cooperate to regulate matrix metalloproteinase-3 gene expression. Int J Cancer. 2011;129(9):2083–2092.
36. Hernandez-Barrantes S, Bernardo M, Toth M, Fridman R. Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol. 2002;12(2):131–138.
37. Adams KM, Lucas J, Kapur RP, Stevens AM. LPS induces translocation of TLR4 in amniotic epithelium. Placenta. 2007;28(5–6):477–481.
38. Zampetaki A, Xiao Q, Zeng L, Hu Y, Xu Q. TLR4 expression in mouse embryonic stem cells and in stem cell-derived vascular cells is regulated by epigenetic modifications. Biochem Biophys Res Commun. 2006;347(1):89–99.
39. Takahashi K, Sugi Y, Hosono A, Kaminogawa S. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J Immunol. 2009;183(10):6522–6529.
40. Bernardo MM, Fridman R. TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J. 2003;374(Pt 3):739–745.